Therapeutic genome editing has great potential to cure some rare diseases, but germline editing is banned. With a broad societal discussion supported by national and transnational legislation, it could be allowed in certain circumstances.
This is a preview of subscription content, log in via an institution to check access.
References
Doudna, J. A. & Charpentier, E. Science 346, 1258096 (2014).
Hsu, P. D. et al. Nat. Biotechnol. 31, 827–832 (2013).
Komor, A. C. et al. Nature 533, 420–424 (2016).
Anzalone, A. V. et al. Nature 576, 149–157 (2019).
Adli, M. Nat. Commun. 9, 1911 (2018).
Frangoul, H. et al. N. Engl. J. Med. 384, 252–260 (2021).
Kaiser, J. Science https://doi.org/10.1126/science.adf8752 (2022).
Musunuru, K. et al. Nature 593, 429–434 (2021).
Kolli, N. et al. Int. J. Mol. Sci. 18, 754 (2017).
Nagata, K. et al. Nat. Commun. 9, 1800 (2018).
Stadtmauer, E. A. et al. Science 367, eaba7365 (2020).
Hu, W. et al. Proc. Natl. Acad. Sci. USA 111, 11461–11466 (2014).
Harper, J. C. et al. Eur. J. Hum. Genet. 26, 12–33 (2018).
Callaway, E. Nature 530, 18–18 (2016).
Isasi, R., Kleiderman, E. & Knoppers, B. M. Science 351, 337–339 (2016).
Acknowledgements
E.B. thanks V. Hatch for support in producing this Comment.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.B. is a paid consultant to Oxford Nanopore and Cantana and a shareholder of Oxford Nanopore.
Rights and permissions
About this article
Cite this article
Birney, E. A society-wide conversation is needed about germline genome editing using CRISPR. Nat Med 30, 30–32 (2024). https://doi.org/10.1038/s41591-023-02681-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02681-1
- Springer Nature America, Inc.
This article is cited by
-
Stringent criteria needed for germline genome editing of human IVF embryos
Journal of Assisted Reproduction and Genetics (2024)